Publications by authors named "Thomas Gesner"

Claim this Profile
A
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity.
Alyssa Synan, Nila C Wu, Roberto Velazquez, Thomas Gesner, Claude Logel

MAbs· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody-Drug Conjugates.
Alexei S Karpov, Tinya Abrams, Suzanna Clark, Ankita Raikar, Joseph A D'Alessio, Thomas G Gesner

ACS Med Chem Lett· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.
Kalli C Catcott, Molly A McShea, Carl Uli Bialucha, Kathy L Miller, Stuart W Hicks, Thomas G Gesner

MAbs· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.
Hetalkumar D Patel, Pavel Nikitin, Thomas Gesner, James J Lin, David T Barkan

Antimicrob Agents Chemother· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3D Pharmacophore Model-Assisted Discovery of Novel CDC7 Inhibitors.
Mika Lindvall, Christopher McBride, Maureen McKenna, Thomas G Gesner, Asha Yabannavar

ACS Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
Cynthia M Shafer, Mika Lindvall, Cornelia Bellamacina, Thomas G Gesner, Asha Yabannavar

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Archie N Tse, Katherine G Rendahl, Tahir Sheikh, Haider Cheema, Kim Aardalen, Thomas G Gesner

Clin Cancer Res· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a screening assay for surrogate markers of CHK1 inhibitor-induced cell cycle release.
Christie P Fanton, Michael W Rowe, Edward J Moler, Marjorie Ison-Dugenny, Susan K De Long, Thomas G Gesner

J Biomol Screen· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors.
Christopher M McBride, Paul A Renhowe, Thomas G Gesner, Johanna M Jansen, Julie Lin

Bioorg Med Chem Lett· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors.
Zhi-Jie Ni, Paul Barsanti, Nathan Brammeier, Anthony Diebes, Daniel J Poon, Thomas G Gesner

Bioorg Med Chem Lett· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis